



# PROGRAM ASSISTANCE LETTER

**DOCUMENT NUMBER: 2022-03**

**DOCUMENT TITLE: Proposed Uniform Data System Changes for Calendar Year 2023**

DATE: August 12, 2022

**TO:** Health Centers  
Health Center Controlled Networks  
Primary Care Associations  
Primary Care Offices  
National Training and Technical Assistance Partners

## **I. BACKGROUND**

This Program Assistance Letter (PAL) provides an overview of proposed changes to the Health Resources and Services Administration's (HRSA) calendar year (CY) 2023 Uniform Data System (UDS) to be reported by Health Center Program awardees and look-alikes in February 2024. Additional details regarding these updates will be provided in the forthcoming 2023 UDS Manual and reporting guidance.

## **II. PROPOSED UPDATES FOR CY 2023 UDS REPORTING**

### **A. UPDATE DEMOGRAPHIC CHARACTERISTICS FOR: TABLE 3B**

To support alignment with Section 4302 of the U.S. Department of Health and Human Services (HHS) Implementation Guidance<sup>1</sup> on Data Standards for expanded Race and Ethnicity (R/E) categories, the UDS will be updated to include sub-group categories for: Asian and Other Pacific Islander, as well as a broader selection for ethnicity through including Hispanic sub-categories. These (R/E) sub-category options will allow for better reflection of the diversity of patients served by health centers as well as continue to align with the Office of Management and Budget's (OMB)<sup>2</sup> minimum categories for race and for ethnicity data collection. Embedded in this document, is an example of Table 3B (Demographic Updates) and Table 7 (Health Outcomes and Disparities) with the expanded R/E sub-categories.

Rationale: Given more than 62% of patients who receive care services at HRSA supported health centers are R/E minorities, the ability to obtain more granular insights on subpopulations, will support health centers in providing more patient-centered and equitable care, as well as support BPHC and its Technical Assistance

<sup>1</sup> <https://aspe.hhs.gov/reports/hhs-implementation-guidance-data-collection-standards-race-ethnicity-sex-primary-language-disability-0#:~:text=Section%204302%20requires%20the%20Secretary,all%20national%20population%20health%20surveys>

<sup>2</sup> <https://www.whitehouse.gov/omb/>

(TA) partner's efforts to advance health equity. Capturing more granular data defined by R/E data will additionally align with HHS' Office of Minority Health (OMH).<sup>3</sup>

## **B. UPDATE STAFFING AND UTILIZATION FOR TABLE 5**

Will be updated to include four distinct lines for reporting Pharmacy Personnel categorized by:

- Pharmacists
- Clinical Pharmacist
- Pharmacy Technicians
- Other Pharmacy Personnel

Rationale: Collecting more granular data on pharmacy personnel, will improve the ability to articulate the critical role that pharmacy personnel play in an integrated primary care setting. Pharmacists and prescription medications are an essential components of a patient's care plan and studies found patients can encounter pharmacists between 1.5 to 10 times more frequently than they encounter primary care physicians<sup>4</sup>. Differentiating pharmacy personnel roles will allow for better granularity and specificity on how pharmacists, clinical pharmacists, technicians, and other pharmacy personnel influence access to medications such as statins, aspirin or antiplatelets, and impact clinical quality measures such as diabetes and hypertension. The scope for each pharmacy personnel category can vary substantially. Depending on the state and jurisdiction, pharmacists and technicians can prepare and distribute patient medications, prepare sterile medications, obtain medication histories and perform reconciliation, and even administer vaccines. Pharmacists play a vital role in public health priorities. Clinical pharmacists typically undergo further residency training and are board certified, enabling them to be integrated into specialized care teams such as ambulatory care, cardiology, oncology, psychiatry, and more. Clinical pharmacists also bridge the patient/provider pharmaceutical gap<sup>5</sup> by interacting with both physician and patient. During the COVID-19 pandemic, pharmacy teams proved to be essential in the testing, administering vaccines<sup>6</sup>, and dispensing of oral antiviral therapies<sup>7</sup>. In the United States, as of July 7, 2022, more than 258.1 million doses of COVID-19 vaccine have been administered and reported by Federal Retail Pharmacy Program participants<sup>8</sup>. A better knowledge of the integration of pharmaceutical care services across health centers will be possible with this data captured. Embedded in this document, is an example of Table 5 updates for Staffing and Utilization.

## **C. UPDATED SELECTED DIAGNOSES AND SERVICES RENDERED: TABLE 6A**

A measure is being added to track the number of children who receive developmental screening and evaluation services. This measure will encompass developmental screening, behavioral testing, and administration assessment, with suggested procedural and diagnostic codes to identify for screening developmental disorders in childhood.

---

<sup>3</sup> <https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=3&lvlid=54>

<sup>4</sup> <https://pubmed.ncbi.nlm.nih.gov/29317929/>

<sup>5</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281611/#:~:text=They%20obtain%20medical%20and%20medication,%2C%20provide%20patient%20counseling%2C%20etc.>

<sup>6</sup> <https://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/participating-pharmacies.html>

<sup>7</sup> <https://www.cdc.gov/mmwr/volumes/71/wr/mm7125e1.htm>

<sup>8</sup> <https://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/index.html>

Rationale: Early childhood is a critical period for physical, cognitive and social development, laying the foundation for life-long health and well-being. Childhood mental, behavioral, and developmental disorders are associated with adverse outcomes that can continue into adulthood<sup>9</sup>. Data show that mental, behavioral and developmental disorders may begin to present in early childhood; 1 in 6 U.S. children aged 2–8 years (17.4%) had a diagnosed mental, behavioral, or developmental disorder<sup>10</sup>. In addition, disparities in care for racial/ethnic minorities, as well as medically underserved populations, are also associated with children’s physical and mental health. Collecting more granular data on early childhood development will help health centers better screen, identify, evaluate, and treat for behavioral conditions in children.

#### **D. UPDATE QUALITY OF CARE MEASURES TO ALIGN WITH E-CQMS: TABLE 6B AND 7**

The following UDS clinical quality measures (CQMs) will be aligned with the versions of the Centers for Medicare and Medicaid Services (CMS) electronic-specified clinical quality measures (eCQMs) designated for the 2023 reporting period.

Rationale: Data-driven quality improvement and optimization of electronic health record (EHR) systems support the delivery of high quality care in health centers. Clinical performance measure alignment across national programs promotes data standardization and quality and decreases reporting burden. Additionally, measure alignment and harmonization with other national quality programs, such as the [National Quality Forum](#) (NQF) and the [CMS Quality Payment Program](#) (QPP), remains a federal priority. Hyperlinks to the Electronic Clinical Quality Improvement (eCQI) <sup>11</sup>Resource Center have been included to provide additional details of the eCQM reporting requirements.

#### **2023 UDS eCQMs**

1. Childhood Immunization Status has been revised to align with [CMS117v11](#)
2. Cervical Cancer Screening has been revised to align with [CMS124v11](#)
3. Breast Cancer Screening has been revised to align with [CMS125v11](#)
4. Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents has been revised to align with [CMS155v11](#)
5. Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan has been revised to align with [CMS69v11](#)
6. Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention has been revised to align with [CMS138v11](#)
7. Statin Therapy for the Prevention and Treatment of Cardiovascular Disease has been revised to align with [CMS347v5](#)
8. Colorectal Cancer Screening has been revised to align with [CMS130v11](#)
9. HIV Screening has been revised to align with [CMS349v5](#)
10. Preventive Care and Screening: Screening for Depression and Follow-Up Plan has been revised to align with [CMS2v11](#)
11. Depression Remission at Twelve Months has been revised to align with [CMS159v11](#)
12. Controlling High Blood Pressure has been revised to align with [CMS165v11](#)
13. Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) has been revised to align with [CMS122v11](#)

---

<sup>9</sup> <https://www.cdc.gov/mmwr/volumes/67/wr/mm6750a1.htm>

<sup>10</sup> <https://www.cdc.gov/childrensmentalhealth/data.html#ref>

<sup>11</sup> <https://ecqi.healthit.gov/>

## E. ACCEPTING UDS+ PATIENT LEVEL REPORTING DATA

Beginning with the 2023 UDS reporting cycle, HRSA will accept patient-level report data using Health Level 7 (HL7®) Fast Healthcare Interoperability Resources (FHIR)<sup>12</sup> standards or alternatively through a manual file upload in fulfillment of Tables:

- Patients by ZIP Code (PBZC) Table
- Table 3A: Patients by Age and by Sex Assigned at Birth
- Table 3B: Demographic Characteristics
- Table 4: Selected Patient Characteristics
- Table 6A: Selected Diagnoses and Services Rendered
- Table 6B: Quality of Care Measures
- Table 7: Health Outcomes and Disparities

Rationale: High-quality accessible data are critical to strategically meeting the needs of patients and identifying opportunities for clinical process improvement. The growth in health information technology coupled with the increased adoption of electronic health records (EHRs) has transformed patient care delivery and underscored the need for secure and rapid exchange of health data between disparate systems. Health Level Seven International (HL7)<sup>13</sup> developed Fast Healthcare Interoperability Resources (FHIR)<sup>14</sup> to standardize the electronic exchange of patient data across systems. FHIR, which is the current gold standard, has the flexibility to support a variety of use cases and enhances interoperability by transmitting health data rapidly and more securely than ever before. It is important for the collection of UDS data to align with interoperability standards and reporting requirements across HHS and the healthcare industry. Leveraging FHIR to collect UDS patient-level data will improve data granularity, allow for the development of robust patient management programs, and improve equitable access to high-quality, cost-effective primary care services.

## F. CONTACTS

For questions or comments regarding the updates to the CY 2022UDS, contact the Office of Quality Improvement at [OQIComments@hrsa.gov](mailto:OQIComments@hrsa.gov).

Sincerely  
/s/ Jim Macrae  
Associate Administrator

Attachments:

1. UDS Table 3B: Demographic Characteristics (expanded categories for Race/Ethnicity)
2. UDS Table 5: Staffing and Utilization (Pharmacy Personnel)
3. UDS Table 6A: Selected Diagnoses and Services Rendered (Early Childhood Development Screening)
4. UDS Table 7: Health Outcomes and Disparities (aligned expanded categories for Race/Ethnicity)

---

<sup>12</sup> <https://www.cdc.gov/nchs/nvss/modernization/pdf/fhir-implimentation-guidance-checklist.pdf>

<sup>13</sup> <https://www.hl7.org/>

<sup>14</sup> <https://ecqi.healthit.gov/fhir>

UDS Table 3B: Demographic Characteristics (expanded categories for Race/Ethnicity)

**Table 3B: Demographic Characteristics**

Calendar Year: January 1, 2023 through December 31, 2023

Line	Patients by Race	Yes, Mexican, Mexican American, Chicano/o (a1)	Yes, Puerto Rican (a2)	Yes, Cuban (a3)	Yes, Another Hispanic, Latino/a or Spanish origin (a4)	Total Hispanic, Latino/a, or Spanish origin (a) (Sum Columns a1+a2+a3+a4)	Not Hispanic, Latino/a, or Spanish origin (b)	Unreported/ Choose Not to Disclose Ethnicity (c)	Total (d) (Sum Columns a+b+c)
1a	Asian Indian								
1b	Chinese								
1c	Filipino								
1d	Japanese								
1e	Korean								
1f	Vietnamese								
1g	Other Asian								
1	Total Asian (Sum Lines 1a+1b+1c+1d+1e+1f+1g)								
2a	Native Hawaiian								
2b	Other Pacific Islander								
2c	Guamanian or Chamorro								
2d	Samoan								
2	Total Native Hawaiian/Other Pacific Islander (Sum Lines 2a + 2b+2c+2d)								
3	Black/African American								
4	American Indian/Alaska Native								
5	White								
6	More than one race								
7	Unreported/Choose not to disclose race								
8	<b>Total Patients</b> (Sum of Lines 1 + 2 + 3 to 7)								

UDS Table 5: Staffing and Utilization (Pharmacy Personnel)

**Table 5: Staffing and Utilization**

Calendar Year: January 1, 2023 through December 31, 2023

Line	Personnel by Major Service Category	FTEs (a)	Clinic Visits (b)	Virtual Visits (b2)	Patients (c)
1	Family Physician				
...					
23a.	Pharmacist				
23b.	Clinical Pharmacist				
23c.	Pharmacy Technician				
23d.	Other Pharmacy Personnel				

UDS Table 6A: Selected Diagnoses and Services Rendered (Early Childhood Development Screening)

**Table 6A: Selected Diagnoses and Services Rendered**

Calendar Year: January 1, 2023 through December 31, 2023

Line	Service Category	Applicable ICD-10-CM , CPT-4/I/II/PLA, or HCPCS Code	Number of Visits by Diagnosis Regardless of Primacy (a)	Number of Patients with Diagnosis (b)
<b>Selected Diagnostic Tests/ Screening/Preventive Services</b>				
21	HIV Test	CPT-4: 86689, 86701 through 86703, 87389 through 87391, 87534 through 87539, 87806		
...				
26	Health supervision of infant or child (ages 0 through 11)	CPT-4: 99381 through 99383, 99391 through 99393 ICD-10: Z00.1-, Z76.1. Z76.2		
26a	Childhood lead test screening (9 to 72 months)	ICD-10: Z13.88 CPT-4: 83655		
26b	Screening, Brief Intervention, and Referral to Treatment (SBIRT)	CPT-4: 99408, 99409 HCPCS: G0396, G0397, G0443, H0050		
26c	Smoke and tobacco use cessation counseling	CPT-4: 99406, 99407 HCPCS: S9075 CPT-II: 4000F, 4001F, 4004F		
26d	Comprehensive and intermediate eye exams	CPT-4: 92002, 92004, 92012, 92014		
26e	Childhood Development Screenings and Evaluations	CPT-4: 96110, 96112, 96113 ICD-10: Z13.4-		

UDS Table 7: Health Outcomes and Disparities (aligned expanded categories for Race/Ethnicity)

**Table 7: Health Outcomes and Disparities**

Calendar Year: January 1, 2023 through December 31, 2023

**Section A: Deliveries and Birth Weight**

Line	Description	Patients (a)
0	HIV-Positive Pregnant Patients	
2	Deliveries Performed by Health Center’s Providers	

Line	Race and Ethnicity	Prenatal Care Patients Who Delivered During the Year (1a)	Live Births: <1500 grams (1b)	Live Births: 1500–2499 grams (1c)	Live Births: ≥2500 grams (1d)
<b>Mexican, Mexican American, Chicano/a</b>					
1a1m	Asian Indian				
1a2m	Chinese				
1a3m	Filipino				
1a4m	Japanese				
1a5m	Korean				
1a6m	Vietnamese				
1a7m	Other Asian				
1b1m	Native Hawaiian				
1b2m	Other Pacific Islander				
1b3m	Guamanian or Chamorro				
1b4m	Samoan				
1cm	Black/African American				
1dm	American Indian/Alaska Native				
1em	White				
1fm	More than One Race				
1gm	Unreported/Chose Not to Disclose Race				
	<i>Subtotal Mexican, Mexican American, Chicano/a</i>				
<b>Puerto Rican</b>					
1a1p	Asian Indian				
1a2p	Chinese				
1a3p	Filipino				
1a4p	Japanese				
1a5p	Korean				
1a6p	Vietnamese				
1a7p	Other Asian				

Line	Race and Ethnicity	Prenatal Care Patients Who Delivered During the Year (1a)	Live Births: <1500 grams (1b)	Live Births: 1500–2499 grams (1c)	Live Births: ≥2500 grams (1d)
1b1p	Native Hawaiian				
1b2p	Other Pacific Islander				
1b3p	Guamanian or Chamorro				
1b4p	Samoan				
1cp	Black/African American				
1dp	American Indian/Alaska Native				
1ep	White				
1fp	More than One Race				
1gp	Unreported/Chose Not to Disclose Race				
	<i>Subtotal Puerto Rican</i>				
<b>Cuban</b>					
1a1c	Asian Indian				
1a2c	Chinese				
1a3c	Filipino				
1a4c	Japanese				
1a5c	Korean				
1a6c	Vietnamese				
1a7c	Other Asian				
1b1c	Native Hawaiian				
1b2c	Other Pacific Islander				
1b3c	Guamanian or Chamorro				
1b4c	Samoan				
1cc	Black/African American				
1dc	American Indian/Alaska Native				
1ec	White				
1fc	More than One Race				
1gc	Unreported/Chose Not to Disclose Race				
	<i>Subtotal Cuban</i>				
<b>Another Hispanic, Latino/a, or Spanish Origin</b>					
1a1a	Asian Indian				
1a2a	Chinese				
1a3a	Filipino				
1a4a	Japanese				
1a5a	Korean				
1a6a	Vietnamese				



Line	Race and Ethnicity	Prenatal Care Patients Who Delivered During the Year (1a)	Live Births: <1500 grams (1b)	Live Births: 1500–2499 grams (1c)	Live Births: ≥2500 grams (1d)
1a7a	Other Asian				
1b1a	Native Hawaiian				
1b2a	Other Pacific Islander				
1b3a	Guamanian or Chamorro				
1b4a	Samoan				
1ca	Black/African American				
1da	American Indian/Alaska Native				
1ea	White				
1fa	More than One Race				
1ga	Unreported/Chose Not to Disclose Race				
	<i>Subtotal Another Hispanic, Latino/a, or Spanish Origin</i>				
	<i>Subtotal Total Hispanic, Latino/a, or Spanish Origin</i>				
<b>Not Hispanic, Latino/a, or Spanish Origin</b>					
2a1	Asian Indian				
2a2	Chinese				
2a3	Filipino				
2a4	Japanese				
2a5	Korean				
2a6	Vietnamese				
2a7	Other Asian				
2b1	Native Hawaiian				
2b2	Other Pacific Islander				
2b3	Guamanian or Chamorro				
2b4	Samoan				
2c	Black/African American				
2d	American Indian/Alaska Native				
2e	White				
2f	More than One Race				
2g	Unreported/Chose Not to Disclose Race				
	<i>Subtotal Total Not Hispanic, Latino/a, or Spanish Origin</i>				
<b>Unreported/Chose Not to Disclose Race and Ethnicity</b>					
h	Unreported/Chose Not to Disclose Race and Ethnicity				
i	<b>Total</b>				

**Section B: Controlling High Blood Pressure**

Line	Race and Ethnicity	Total Patients 18 through 84 Years of Age with Hypertension (2a)	Number of Records Reviewed (2b)	Patients with Hypertension Controlled (2c)
<b>Mexican, Mexican American, Chicano/a</b>				
1a1m	Asian Indian			
1a2m	Chinese			
1a3m	Filipino			
1a4m	Japanese			
1a5m	Korean			
1a6m	Vietnamese			
1a7m	Other Asian			
1b1m	Native Hawaiian			
1b2m	Other Pacific Islander			
1b3m	Guamanian or Chamorro			
1b4m	Samoa			
1cm	Black/African American			
1dm	American Indian/Alaska Native			
1em	White			
1fm	More than One Race			
1gm	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Mexican, Mexican American, Chicano/a</i>			
<b>Puerto Rican</b>				
1a1p	Asian Indian			
1a2p	Chinese			
1a3p	Filipino			
1a4p	Japanese			
1a5p	Korean			
1a6p	Vietnamese			
1a7p	Other Asian			
1b1p	Native Hawaiian			
1b2p	Other Pacific Islander			
1b3p	Guamanian or Chamorro			
1b4p	Samoa			
1cp	Black/African American			

Line	Race and Ethnicity	Total Patients 18 through 84 Years of Age with Hypertension (2a)	Number of Records Reviewed (2b)	Patients with Hypertension Controlled (2c)
1dp	American Indian/Alaska Native			
1ep	White			
1fp	More than One Race			
1gp	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Puerto Rican</i>			
<b>Cuban</b>				
1a1c	Asian Indian			
1a2c	Chinese			
1a3c	Filipino			
1a4c	Japanese			
1a5c	Korean			
1a6c	Vietnamese			
1a7c	Other Asian			
1b1c	Native Hawaiian			
1b2c	Other Pacific Islander			
1b3c	Guamanian or Chamorro			
1b4c	Samoan			
1cc	Black/African American			
1dc	American Indian/Alaska Native			
1ec	White			
1fc	More than One Race			
1gc	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Cuban</i>			
<b>Another Hispanic, Latino/a, or Spanish Origin</b>				
1a1a	Asian Indian			
1a2a	Chinese			
1a3a	Filipino			
1a4a	Japanese			
1a5a	Korean			
1a6a	Vietnamese			
1a7a	Other Asian			
1b1a	Native Hawaiian			
1b2a	Other Pacific Islander			

Line	Race and Ethnicity	Total Patients 18 through 84 Years of Age with Hypertension (2a)	Number of Records Reviewed (2b)	Patients with Hypertension Controlled (2c)
1b3a	Guamanian or Chamorro			
1b4a	Samoan			
1ca	Black/African American			
1da	American Indian/Alaska Native			
1ea	White			
1fa	More than One Race			
1ga	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Another Hispanic, Latino/a, or Spanish Origin</i>			
	<i>Subtotal Total Hispanic, Latino/a, or Spanish Origin</i>			
<b>Not Hispanic, Latino/a, or Spanish Origin</b>				
2a1	Asian Indian			
2a2	Chinese			
2a3	Filipino			
2a4	Japanese			
2a5	Korean			
2a6	Vietnamese			
2a7	Other Asian			
2b1	Native Hawaiian			
2b2	Other Pacific Islander			
2b3	Guamanian or Chamorro			
2b4	Samoan			
2c	Black/African American			
2d	American Indian/Alaska Native			
2e	White			
2f	More than One Race			
2g	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Total Not Hispanic, Latino/a, or Spanish Origin</i>			
<b>Unreported/Chose Not to Disclose Race and Ethnicity</b>				

Line	Race and Ethnicity	Total Patients 18 through 84 Years of Age with Hypertension (2a)	Number of Records Reviewed (2b)	Patients with Hypertension Controlled (2c)
h	Unreported/Chose Not to Disclose Race and Ethnicity			
i	<b>Total</b>			

**Section C: Diabetes: Hemoglobin A1c Poor Control**

Line	Race and Ethnicity	Total Patients 18 through 74 Years of Age with Diabetes (3a)	Number of Records Reviewed (3b)	Patients with HbA1c >9.0% or No Test During Year (3f)
	<b>Mexican, Mexican American, Chicano/a</b>			
1a1m	Asian Indian			
1a2m	Chinese			
1a3m	Filipino			
1a4m	Japanese			
1a5m	Korean			
1a6m	Vietnamese			
1a7m	Other Asian			
1b1m	Native Hawaiian			
1b2m	Other Pacific Islander			
1b3m	Guamanian or Chamorro			
1b4m	Samoan			
1cm	Black/African American			
1dm	American Indian/Alaska Native			
1em	White			
1fm	More than One Race			
1gm	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Mexican, Mexican American, Chicano/a</i>			
	<b>Puerto Rican</b>			
1a1p	Asian Indian			
1a2p	Chinese			
1a3p	Filipino			
1a4p	Japanese			
1a5p	Korean			
1a6p	Vietnamese			
1a7p	Other Asian			
1b1p	Native Hawaiian			
1b2p	Other Pacific Islander			

Line	Race and Ethnicity	Total Patients 18 through 74 Years of Age with Diabetes (3a)	Number of Records Reviewed (3b)	Patients with HbA1c >9.0% or No Test During Year (3f)
1b3p	Guamanian or Chamorro			
1b4p	Samoan			
1cp	Black/African American			
1dp	American Indian/Alaska Native			
1ep	White			
1fp	More than One Race			
1gp	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Puerto Rican</i>			
	<b>Cuban</b>			
1a1c	Asian Indian			
1a2c	Chinese			
1a3c	Filipino			
1a4c	Japanese			
1a5c	Korean			
1a6c	Vietnamese			
1a7c	Other Asian			
1b1c	Native Hawaiian			
1b2c	Other Pacific Islander			
1b3c	Guamanian or Chamorro			
1b4c	Samoan			
1cc	Black/African American			
1dc	American Indian/Alaska Native			
1ec	White			
1fc	More than One Race			
1gc	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Cuban</i>			
	<b>Another Hispanic, Latino/a, or Spanish Origin</b>			
1a1a	Asian Indian			
1a2a	Chinese			
1a3a	Filipino			
1a4a	Japanese			
1a5a	Korean			
1a6a	Vietnamese			
1a7a	Other Asian			
1b1a	Native Hawaiian			
1b2a	Other Pacific Islander			

Line	Race and Ethnicity	Total Patients 18 through 74 Years of Age with Diabetes (3a)	Number of Records Reviewed (3b)	Patients with HbA1c >9.0% or No Test During Year (3f)
1b3a	Guamanian or Chamorro			
1b4a	Samoan			
1ca	Black/African American			
1da	American Indian/Alaska Native			
1ea	White			
1fa	More than One Race			
1ga	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Another Hispanic, Latino/a, or Spanish Origin</i>			
	<i>Subtotal Total Hispanic, Latino/a, or Spanish Origin</i>			
	<b>Not Hispanic, Latino/a, or Spanish Origin</b>			
2a1	Asian Indian			
2a2	Chinese			
2a3	Filipino			
2a4	Japanese			
2a5	Korean			
2a6	Vietnamese			
2a7	Other Asian			
2b1	Native Hawaiian			
2b2	Other Pacific Islander			
2b3	Guamanian or Chamorro			
2b4	Samoan			
2c	Black/African American			
2d	American Indian/Alaska Native			
2e	White			
2f	More than One Race			
2g	Unreported/Chose Not to Disclose Race			
	<i>Subtotal Total Not Hispanic, Latino/a, or Spanish Origin</i>			
	<b>Unreported/Chose Not to Disclose Race and Ethnicity</b>			
h	Unreported/Chose Not to Disclose Race and Ethnicity			
i	<b>Total</b>			